Last reviewed · How we verify

Gram-Negative Aerobic Bacillary Pneumonia — Treatment Landscape & Competitive Intelligence

Gram-Negative Aerobic Bacillary Pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gram-Negative Aerobic Bacillary Pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Cipro ciprofloxacin Bayer AG Fluoroquinolone antibiotic DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A 1987-10-22
Azactam AZTREONAM Bristol-Myers Squibb Monobactam Antibacterial [EPC] 1986-01-01
Primaxin CILASTATIN Merck & Co. Renal Dehydropeptidase Inhibitor Dipeptidase 1 1985-01-01
Primaxin IMIPENEM Merck Sharp & Dohme B.V. imipenem 1985-01-01
Rocephin ceftriaxone Generic (originally Roche) Cephalosporin antibiotic (third-generation) Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A 1984-12-21
Arikayce Kit AMIKACIN Bristol-Myers Squibb Aminoglycoside Antibacterial 1981-01-01
Vantobra Tobramycin Sulfate Pfizer tobramycin Taste receptor type 2 member 20 1974-01-01
Garamycin GENTAMICIN Merck & Co. Aminoglycoside Antibacterial Transient receptor potential cation channel subfamily V member 5 1970-01-01
Gentamicin Gentamicin Sulfate Merck & Co. gentamicin Dihydrofolate reductase 1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merck & Co. · 3 drugs in Gram-Negative Aerobic Bacillary Pneumonia
  2. · 3 drugs in Gram-Negative Aerobic Bacillary Pneumonia
  3. Bristol-Myers Squibb · 2 drugs in Gram-Negative Aerobic Bacillary Pneumonia
  4. Centre Hospitalier Universitaire Vaudois · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  5. Generic (originally Daiichi Sankyo/J&J) · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  6. Generic (originally Roche) · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  7. Merck Sharp & Dohme B.V. · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  8. Novartis · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  9. Pfizer · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  10. Poitiers University Hospital · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  11. University Hospital, Lille · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia
  12. Assistance Publique - Hôpitaux de Paris · 1 drug in Gram-Negative Aerobic Bacillary Pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gram-Negative Aerobic Bacillary Pneumonia:

Cite this brief

Drug Landscape (2026). Gram-Negative Aerobic Bacillary Pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gram-negative-aerobic-bacillary-pneumonia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing